Studies of Velcade Show Emerging Role as Cornerstone of MM Care

Millennium Pharmaceuticals has presented positive clinical results for Velcade in treating patients across the multiple myeloma (MM) treatment paradigm, including data regarding the use of Velcade as a single agent and in combination with standard and emerging MM therapies.

The data provided evidence for the potential of Velcade to induce higher response rates in earlier lines of therapy. Front-line studies of Velcade showed very high response rates in previously untreated MM patients with manageable toxicities. These studies were the basis for three large, multicenter, independent Phase III studies. Velcade is approved in the U.S. for the treatment of patients who have received at least one prior therapy.